investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Extraordinary responder cell lines reveal unique targetable genetic dependencies
Hugh S. Gannon
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Hugh S. Gannon
Dana-Farber Cancer Institute
Boston, United States
Related projects
David E Goldgar
A Comprehensive Approach to Breast Cancer Susceptibility Across the Risk Spectrum
Breast
Leonard Neckers
Role of HSP90 Family Chaperone Proteins in Cellular Signal Transduction
Breast
Barbara M Mueller
A Novel Plasminogen Receptor in Breast Cancer
Breast
Susan Bates
Clinical Studies to Circumvent Drug Resistance
Breast
Heide L Ford
Role of Six1 and the miR106b 25 Cluster in EMT and Tumor Progression
Breast
Michael J Holliday
Mapping and Controlling the Segmental Dynamic Networks of Cyclophilin A as they Relate to Enzymatic Function
Breast
William G Kaelin
The RBP2/JARID1A/KDM5A Histone Demethylase as a Potential Drug Target in Cancer
Breast
Donald W. Kufe
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
Breast
Marie C. Lee
Development of the Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk
Breast